{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:55:12Z","timestamp":1780761312724,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Atherogenic dyslipidemia (AD), characterized by increased concentrations of apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 diabetes mellitus (T2DM). Non-high-density lipoprotein cholesterol (non-HDL-C), cholesterol transported by apolipoprotein B (ApoB)-containing particles), and total apoB are considered secondary goals of lipid-lowering therapy to guide treatment of residual cardiovascular risk. The BANTING and BERSON studies demonstrated that evolocumab added to statin therapy reduced atherogenic lipid and lipoproteins concentrations in patients with T2DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This post-hoc analysis combined data from two randomized, placebo-controlled trials, BANTING and BERSON, to investigate the effect of evolocumab (140\u00a0mg every two weeks [Q2W] or 420\u00a0mg monthly [QM]) on atherogenic lipid (LDL-C, non-HDL-C, VLDL-C, remnant cholesterol) and lipoproteins (ApoB, lipoprotein(a) (Lp[a])), and achievement of 2019 European Society of Cardiology\/European Atherosclerosis Society lipid treatment goals in individuals with and without AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In individuals with high TGs with (n\u2009=\u2009389) and without (n\u2009=\u2009196) AD receiving background statin therapy, evolocumab, compared with placebo, substantially reduced the cholesterol levels from all ApoB atherogenic lipoproteins (least squares (LS) mean LDL-C by 66.7% to 74.3%, non-HDL-C by 53.4% to 65.8%, median remnant cholesterol by 28.9% to 34.2%, VLDL-C by 16.1% to 19.6%) and median TGs levels (by 17.5% to 19.6%) at the mean of weeks 10 and 12. LS mean ApoB was significantly reduced by 41.5% to 56.6% at week 12. Results were consistent in diabetic individuals with normal TGs (n\u2009=\u2009519). Evolocumab was also associated with a significant reduction in median Lp(a) by 35.0% to 53.9% at the mean of weeks 10 and 12. A majority (74.7% to 79.8%) of evolocumab-treated individuals achieved the goal of both an LDL-C\u2009&lt;\u20091.4\u00a0mmol\/L and an LDL-C reduction of at least 50%,\u2009&gt;\u200975% achieved non-HDL-C\u2009&lt;\u20092.2\u00a0mmol\/L at the mean of weeks 10 and 12, and\u2009&gt;\u200967% achieved ApoB\u2009&lt;\u200965\u00a0mg\/dL at week 12.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Evolocumab effectively reduced LDL-C, non-HDL-C, ApoB, Lp(a), and remnant cholesterol in individuals with T2DM with and without AD. Evolocumab Q2W or QM enabled most individuals at high\/very-high cardiovascular disease risk to achieve their LDL-C, non-HDL-C, and ApoB recommended goals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-021-01287-6","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T09:03:22Z","timestamp":1620032602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-2010","authenticated-orcid":false,"given":"Alberto J.","family":"Lorenzatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Monsalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Antonio G.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"issue":"2","key":"1287_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/01.CIR.82.2.495","volume":"82","author":"MA Austin","year":"1990","unstructured":"Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82(2):495\u2013506.","journal-title":"Circulation"},{"key":"1287_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15420\/ecr.2019.06","volume":"15","author":"AJ Lorenzatti","year":"2020","unstructured":"Lorenzatti AJ, Toth PP. New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol Rev. 2020;15:1\u20139.","journal-title":"Eur Cardiol Rev"},{"issue":"2","key":"1287_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","volume":"52","author":"WT Garvey","year":"2003","unstructured":"Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52(2):453\u201362.","journal-title":"Diabetes"},{"issue":"1","key":"1287_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12872-017-0591-5","volume":"17","author":"JP Halcox","year":"2017","unstructured":"Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, Perk J, Hajage D, Henriksson KM, Borghi C. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17(1):160.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"1287_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"24","key":"1287_CR6","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","volume":"34","author":"AB J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34(24):1826\u201333.","journal-title":"Eur Heart J"},{"issue":"5","key":"1287_CR7","doi-asserted-by":"publisher","first-page":"e002765","DOI":"10.1161\/JAHA.115.002765","volume":"5","author":"PH Joshi","year":"2016","unstructured":"Joshi PH, Khokhar AA, Massaro JM, Lirette ST, Griswold ME, Martin SS, Blaha MJ, Kulkarni KR, Correa A, D\u2019Agostino RB, et al. Remnant lipoprotein cholesterol and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. J Am Heart Assoc. 2016;5(5):e002765.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"1287_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M Miller","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1287_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547\u201363.","journal-title":"Circ Res"},{"issue":"4","key":"1287_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450\u20138.","journal-title":"Circulation"},{"issue":"3","key":"1287_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","volume":"61","author":"A Varbo","year":"2015","unstructured":"Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin Chem. 2015;61(3):533\u201343.","journal-title":"Clin Chem"},{"issue":"9438","key":"1287_CR12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352.","journal-title":"Lancet"},{"issue":"3","key":"1287_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","volume":"259","author":"PJ Barter","year":"2006","unstructured":"Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel. J Intern Med. 2006;259(3):247\u201358.","journal-title":"J Intern Med"},{"issue":"1","key":"1287_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13059","volume":"288","author":"A Langsted","year":"2020","unstructured":"Langsted A, Madsen CM, Nordestgaard BG. Contribution of remnant cholesterol to cardiovascular risk. J Intern Med. 2020;288(1):116\u201327.","journal-title":"J Intern Med"},{"issue":"22","key":"1287_CR15","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"issue":"21","key":"1287_CR16","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","volume":"65","author":"GG Schwartz","year":"2015","unstructured":"Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65(21):2267\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1287_CR17","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1161\/STROKEAHA.113.004229","volume":"45","author":"G Sirimarco","year":"2014","unstructured":"Sirimarco G, Labreuche J, Bruckert E, Goldstein LB, Fox KM, Rothwell PM, Amarenco P. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke. 2014;45(5):1429\u201336.","journal-title":"Stroke"},{"issue":"2","key":"1287_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40256-018-0312-1","volume":"19","author":"K Takata","year":"2019","unstructured":"Takata K, Nicholls SJ. Tackling residual atherosclerotic risk in statin-treated adults: focus on emerging drugs. Am J Cardiovas Drugs Drugs Devices Intervent. 2019;19(2):113\u201331.","journal-title":"Am J Cardiovas Drugs Drugs Devices Intervent"},{"issue":"2","key":"1287_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"1","key":"1287_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr Pract . 2020;26(1):107\u201339.","journal-title":"Endocr Pract"},{"issue":"25","key":"1287_CR21","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"11","key":"1287_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/j.1464-5491.2011.03360.x","volume":"28","author":"LA Leiter","year":"2011","unstructured":"Leiter LA, Lundman P, da Silva PM, Drexel H, J\u00fcnger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011;28(11):1343\u201351.","journal-title":"Diabet Med"},{"key":"1287_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijcard.2018.04.068","volume":"268","author":"C Breuker","year":"2018","unstructured":"Breuker C, Clement F, Mura T, Macioce V, Castet-Nicolas A, Audurier Y, Boegner C, Morcrette E, Jalabert A, Villiet M, et al. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors. Int J Cardiol. 2018;268:195\u20139.","journal-title":"Int J Cardiol"},{"issue":"6","key":"1287_CR24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/dom.13680","volume":"21","author":"AJ Lorenzatti","year":"2019","unstructured":"Lorenzatti AJ, Eliaschewitz FG, Chen Y, Lu J, Baass A, Monsalvo ML, Wang N, Hamer AW, Ge J. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. Diab Obes Metab. 2019;21(6):1455\u201363.","journal-title":"Diab Obes Metab"},{"issue":"6","key":"1287_CR25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","volume":"62","author":"RS Rosenson","year":"2019","unstructured":"Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019;62(6):948\u201358.","journal-title":"Diabetologia"},{"issue":"12","key":"1287_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diab Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diab Endocrinol"},{"issue":"2","key":"1287_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","volume":"6","author":"P Deedwania","year":"2021","unstructured":"Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, et al. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2021;6(2):139\u201347.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"1287_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jacc.2020.11.011","volume":"77","author":"K Oyama","year":"2021","unstructured":"Oyama K, Furtado RHM, Fagundes A Jr, Zelniker TA, Tang M, Kuder J, Murphy SA, Hamer A, Wang H, Keech AC, et al. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2021;77(3):259\u201367.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1287_CR29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/clc.23018","volume":"41","author":"AJ Lorenzatti","year":"2018","unstructured":"Lorenzatti AJ, Eliaschewitz FG, Chen Y, Fialkow J, Lu J, Baass A, Monsalvo ML, Hsu HC, Somaratne R, Ge J. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial. Clin Cardiol. 2018;41(9):1117\u201322.","journal-title":"Clin Cardiol"},{"key":"1287_CR30","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) JAMA 2001, 285(19):2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"issue":"7","key":"1287_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","volume":"57","author":"S Kasichayanula","year":"2018","unstructured":"Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018;57(7):769\u201379.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1287_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","volume":"28","author":"A Varbo","year":"2017","unstructured":"Varbo A, Nordestgaard BG. Remnant lipoproteins. Curr Opin Lipidol. 2017;28(4):300\u20137.","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"1287_CR33","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/clc.23049","volume":"41","author":"E Stroes","year":"2018","unstructured":"Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018;41(10):1328\u201335.","journal-title":"Clin Cardiol"},{"issue":"18","key":"1287_CR34","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870\u201382.","journal-title":"JAMA"},{"issue":"3","key":"1287_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.amjcard.2017.10.028","volume":"121","author":"PP Toth","year":"2018","unstructured":"Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D. Effect of evolocumab on lipoprotein particles. Am J Cardiol. 2018;121(3):308\u201314.","journal-title":"Am J Cardiol"},{"key":"1287_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1475-2840-10-20","volume":"10","author":"MP Hermans","year":"2011","unstructured":"Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol. 2011;10:20.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1287_CR37","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0002-9149(03)00262-5","volume":"91","author":"AD Sniderman","year":"2003","unstructured":"Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despr\u00e9s JP, Lamarche B. Concordance\/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003;91(10):1173\u20137.","journal-title":"Am J Cardiol"},{"issue":"24","key":"1287_CR38","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u201384.","journal-title":"Eur Heart J"},{"issue":"23","key":"1287_CR39","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","volume":"76","author":"M Balling","year":"2020","unstructured":"Balling M, Afzal S, Varbo A, Langsted A, Davey Smith G, Nordestgaard BG. VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins. J Am Coll Cardiol. 2020;76(23):2725\u201335.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1287_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.pharmthera.2013.11.008","volume":"141","author":"A Varbo","year":"2014","unstructured":"Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141(3):358\u201367.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1287_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s12265-014-9559-3","volume":"7","author":"A Sharma","year":"2014","unstructured":"Sharma A, Joshi PH, Rinehart S, Thakker KM, Lele A, Voros S. Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia. J Cardiovasc Transl Res. 2014;7(4):465\u201374.","journal-title":"J Cardiovasc Transl Res"},{"key":"1287_CR42","doi-asserted-by":"crossref","unstructured":"Taskinen MR, Bj\u00f6rnson E, Kahri J, S\u00f6derlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V et al: Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. Arteriosclerosis, thrombosis, and vascular biology 2020:Atvbaha120315446.","DOI":"10.1161\/ATVBAHA.120.315446"},{"issue":"5","key":"1287_CR43","doi-asserted-by":"publisher","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"M Canuel","year":"2013","unstructured":"Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE. 2013;8(5):e64145.","journal-title":"PLoS ONE"},{"issue":"4","key":"1287_CR44","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283(4):2363\u201372.","journal-title":"J Biol Chem"},{"key":"1287_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijcard.2020.05.055","volume":"316","author":"L De Luca","year":"2020","unstructured":"De Luca L, Arca M, Temporelli PL, Meessen J, Riccio C, Bonomo P, Colavita AR, Gabrielli D, Gulizia MM, Colivicchi F. Current lipid lowering treatment and attainment of LDL targets recommended by ESC\/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry. Int J Cardiol. 2020;316:229\u201335.","journal-title":"Int J Cardiol"},{"key":"1287_CR46","doi-asserted-by":"crossref","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D et al: EU-Wide Cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. European Journal of Preventive Cardiology 2020.","DOI":"10.1093\/eurjpc\/zwaa047"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01287-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01287-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01287-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T10:18:31Z","timestamp":1667038711000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01287-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01287-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As noted in the primary reports of the BERSON [, ] and BANTING [] studies, all participants gave informed consent to participate, and the study protocols and amendments were approved by the appropriate ethics review boards at each study site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AJ Lorenzatti was the Principal Investigator in the BERSON trial and reports research support from Amgen, Novo Nordisk and Esperion; a consulting role for Amgen, Kowa, and PTC; and speaking activities with Amgen, Novo Nordisk, Pfizer, and PTC. RS Rosenson reports research support from Amgen, Novartis, NIH, and Regeneron; consulting\/advisory roles for Amgen, Amyrt C5, CVS Caremark, The Medicines Company, Novartis, Regeneron, and 89 BioMedicines Company; speaking (non-promotional) roles with Amgen, Kowa, and Regeneron; stock holdings with MediMergent; royalties from Wolters Kluwer (UpToDate); and patents for biocellular inflammatory pathways. ML Monsalvo, JAG L\u00f3pez, and H Wang are employees and shareholders of Amgen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}